


REMARKS

Claims 73 to 203 are now pending in this application. Applicants have canceled claims 1 to 72 without prejudice and have added new claims 73 to 203. Support for the new claims can be found throughout the specification, e.g., at page 6, lines 21 to 25; page 7, lines 6 to 22; page 8, lines 11 to 22; page 9, lines 9 to 13; page 10, lines 8 to 23; page 11, lines 9 to 19; page 13, lines 1 to 4; page 21, lines 24 to 27; page 23, line 29 to page 24, line 12; page 23, lines 5 to 7; page 31, lines 3 to 6; page 39, lines 7 to 10 and lines 13 to 17; page 49, lines 1 and 2; page 66, line 30 to page 67, line 2; page 72, lines 13 to 17; and claim 62 as originally filed. Claims 185 to 202 are similar in scope to claims 1 to 19 as issued in U.S. Patent No. 6,635,666, except that they recite a step of "identifying a human patient." The new claims add no new matter to the application.

The Commissioner is hereby authorized to charge any fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852


Oona A. Jackson
Attorney for Applicants
Reg. No. 48,152

Date: 3/23/05